Results 211 to 220 of about 93,221 (259)

Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysis. [PDF]

Ther Adv Med Oncol
Zhang X, Zhao W, Wang W, Wu J, Fan M, Ma S, Dong M, Zhu L, Wu X, Feng X, Li X, Li L, Sun Z, Wang X, Fu X, Li Z, Yan J, Chang Y, Yu H, Nan F, Zhou Z, Ding M, Zhang J, Zhang L, Zhang M.   +24 more
europepmc   +1 more source

In vitro assays as a tool to personalize treatment in central nervous system tumors: a systematic literature review. [PDF]

Clin Exp Med
Offi M, Buccarelli M, Chiesa S, Mazzarella C, Falchetti ML, Ceccarelli GM, Di Monaco G, Cocilovo FM, Taglialatela M, Shetty S, Olivi A, Lauretti L, Pallini R, Ricci-Vitiani L, D'Alessandris QG.   +14 more
europepmc   +1 more source

Recurrent hematological toxicity after second-line treatment in patients with glioblastoma: indication of a potential predisposition. [PDF]

Oncologist
van Hout L, van den Elzen FEL, de Jong Z, Grun N, Broen MPG, Bartelink I, Bruynzeel AME, Lagerwaard FJ, Buter J, Vandertop WP, Westerman BA, Lissenberg-Witte BI, Kouwenhoven MCM.   +12 more
europepmc   +1 more source

Vebreltinib for Previously Treated Astrocytoma, <i>IDH</i>-Mutant, Grade 4, and Glioblastoma, <i>IDH</i> Wild-Type with <i>PTPRZ1-MET</i> Fusion Gene: A Multicenter, Phase III Randomized, Open-Label Trial. [PDF]

Cancer Commun (Lond)
Bao Z, Xue Y, Liu Y, Li S, Wang L, Qu Y, Mou Y, Yu R, Wu J, Yao Y, Shu K, Hu G, Cai L, Li W, Qiu X, Li Y, Zhang L, Qi S, Ji Y, Ma C, Ma W, Li G, Tao R, Sun C, Chen L, Lv SQ, Liang P, Pan H, Peter WYM, Danny CTM, Mao Q, Wei X, Jiang T.   +32 more
europepmc   +1 more source

Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy. [PDF]

Contemp Clin Trials Commun
Sener U, Galloway T, Neth B, Uhm J, Kizilbash SH, Campian JL, Caron S, Breen WG, Lehrer E, Golembiewski E, Schultz S, Hughes H, Steinmetz S, Geyer S, Mead-Harvey C, Huebert C, Tauer W, Mason C, Burns TC, Pritchett J, Haddad T.   +20 more
europepmc   +1 more source

Adjuvant chemoradiotherapy with procarbazine, lomustine, and vincristine (PCV) or temozolomide for 1p/19q Co-deleted anaplastic oligodendroglioma: a systematic review and network meta-analysis. [PDF]

BMC Cancer
Santos MDC, Rodrigues NMV, Gibram F, Gouhie FA, Campos ACP, de Assis DV, Formentin C, Feher O, de Souza E Silva ARN, Hanna SA, Chung C, Barbosa CC, Moraes FY, Maldaun MVC.   +13 more
europepmc   +1 more source

Radiomics of T2-weighted MRI for pretreatment prediction of prognosis and temozolomide chemosensitivity in glioma. [PDF]

BMC Cancer
Zhao C, Huang R, Li X, Tang K, Ding J, Li Y, Cui Z, Zhao Z, Zhang W, Qian Z.   +9 more
europepmc   +1 more source

Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma. [PDF]

JCI Insight
Lukas RV, Du R, Congivaram H, McCortney K, Dixit K, Horbinski C, Schwartz M, Lezon R, Singer L, Primdahl D, Thakkar J, Heimberger AB, Stupp R, Kumthekar P.   +13 more
europepmc   +1 more source

Alterations of the tumor microenvironment (TME) by exploratory gene expression analysis in recurrent glioblastoma following apatinib in combination with temozolomide. [PDF]

Biochem Biophys Rep
Ge J, Li C, Xue F, Zhao C, Kong C, Qi S, Duan Q, Zhang Q, Zhang J.   +8 more
europepmc   +1 more source

Ivosidenib treatment in IDH-mutant WHO grade 4 astrocytomas: illustrative case. [PDF]

J Neurosurg Case Lessons
Adjei BO, Renterghem JP, Hayes Meizoso C, Daci R, Mietus CJ, Amenta PS, Johnson MD, Cachia D.   +7 more
europepmc   +1 more source